Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

NCT00407121 | Withdrawn Phase 3

• 1 other identifier: APEC-0025
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Conditions

Vogt Koyanagi Harada Disease; Serpiginous Choroiditis; Multifocal Choroiditis

Keywords

Neovascular Membrane; Uveitis; Bevacizumab

Outcome Measures

Primary Outcomes (3)

• Best corrected visual acuity

• Retinal thickness by OCT

• Leakage in Fluorescein angiogram

Interventions

Bevacizumab DRUG

Intravitreal Injection of Bevacizumab PROCEDURE

Eligibility Criteria

• Age: 25 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Clinical Diagnose
• Patient Consent
• Chronic stage of inflammation

You may not qualify if:

• only eye
• age lower than 30 yo.
• Systemic condition

Sponsors & Collaborators

• Asociación para Evitar la Ceguera en México: lead

Study Sites (1)

Asociacion para Evitar la Ceguera en Mexico

Mexico City, Mexico City, 04030, Mexico

Location

MeSH Terms

Conditions

Uveomeningoencephalitic Syndrome; White Dot Syndromes; Multifocal Choroiditis; Uveitis

Interventions

Bevacizumab

Condition Hierarchy (Ancestors)

Autoimmune Diseases of the Nervous System; Nervous System Diseases; Uveal Diseases; Eye Diseases; Autoimmune Diseases; Immune System Diseases; Uveitis, Posterior; Panuveitis; Choroiditis; Choroid Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Veronica Kon-Jara, MD

  Asociación para Evitar la Ceguera en México

  PRINCIPAL INVESTIGATOR

• LuzElena Concha-Del Rio, MD

  Asociación para Evitar la Ceguera en México

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 1, 2006
• First Posted: December 4, 2006
• Study Start: December 1, 2006
• Primary Completion: December 1, 2006
• Study Completion: December 1, 2006
• Last Updated: May 30, 2024

Record last verified: 2024-05

Locations

ME (1)